Turn Therapeutics presents GX-03 Phase 2a data for atopic dermatitis
TTRX•A 25-patient Phase 2a subgroup showed week-four vIGA-AD success of 61.5% with GX-03, compared with 8.3% with vehicle. Turn Therapeutics expects Phase 2 topline results in the first quarter of 2027 and plans a Phase 3 start in mid-2027.
1. Trial data and timeline
In a 25-patient Phase 2a subgroup, week-four vIGA-AD success was 61.5% with GX-03 versus 8.3% with vehicle. Turn Therapeutics expects first-quarter 2027 topline results from its ongoing Phase 2 trial in moderate-to-severe atopic dermatitis, which targets approximately 120-136 patients. Phase 3 initiation for atopic dermatitis is planned for mid-2027, with a potential commercial launch in 2029. The company also targets a second-quarter 2027 start for a Phase 3-ready GX-03 trial in onychomycosis.
